Twist Bioscience (NASDAQ:TWST) Earns Sell Rating from BWS Financial

Twist Bioscience (NASDAQ:TWST)‘s stock had its “sell” rating reissued by BWS Financial in a research report issued on Friday, Benzinga reports. They presently have a $45.00 price target on the stock. BWS Financial’s target price would suggest a potential downside of 71.68% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Guggenheim reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a research report on Monday, July 6th. Piper Sandler increased their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Barclays raised their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $103.00.

Twist Bioscience Price Performance

Shares of TWST stock opened at $158.90 on Friday. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $163.70. The firm has a market capitalization of $9.96 billion, a price-to-earnings ratio of -71.87 and a beta of 2.22. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average of $117.46 and a 200-day moving average of $82.21.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 EPS. On average, equities research analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 2,399 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer owned 110,276 shares in the company, valued at approximately $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 41,570 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the completion of the transaction, the chief executive officer directly owned 770,729 shares of the company’s stock, valued at approximately $117,135,393.42. This trade represents a 5.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 193,109 shares of company stock worth $24,049,024. Company insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently modified their holdings of the stock. William Blair Investment Management LLC raised its stake in Twist Bioscience by 43.7% in the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after purchasing an additional 1,812,146 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $600,191,000. Bank of America Corp DE acquired a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $94,922,000. Allspring Global Investments Holdings LLC bought a new position in shares of Twist Bioscience during the first quarter worth approximately $22,563,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Twist Bioscience by 242.2% during the fourth quarter. BNP Paribas Financial Markets now owns 415,609 shares of the company’s stock worth $13,183,000 after purchasing an additional 294,144 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.